## Michel Moutschen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5461098/publications.pdf

Version: 2024-02-01

104 papers 4,445 citations

30 h-index 62 g-index

109 all docs

109 docs citations

109 times ranked 7188 citing authors

#	Article	IF	CITATIONS
1	Therapeutic options for CTLA-4 insufficiency. Journal of Allergy and Clinical Immunology, 2022, 149, 736-746.	1.5	68
2	Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. Aging Clinical and Experimental Research, 2022, 34, 223-234.	1.4	16
3	University population-based prospective cohort study of SARS-CoV-2 infection and immunity (SARSSURV-ULià ge): a study protocol. BMJ Open, 2022, 12, e055721.	0.8	6
4	Modalities and preferred routes of geographic spread of cholera from endemic areas in eastern Democratic Republic of the Congo. PLoS ONE, 2022, 17, e0263160.	1.1	2
5	Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the †treat-all†strategy. PLOS Global Public Health, 2022, 2, e0000259.	0.5	6
6	Clinical epidemiology and high genetic diversity amongst Cryptococcus spp. isolates infecting people living with HIV in Kinshasa, Democratic Republic of Congo. PLoS ONE, 2022, 17, e0267842.	1.1	3
7	Evaluation of Screening Program and Phylogenetic Analysis of SARS-CoV-2 Infections among Hospital Healthcare Workers in Liège, Belgium. Viruses, 2022, 14, 1302.	1.5	2
8	Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 160-169.	2.0	52
9	Immunosuppression Withdrawal After Liver Transplantation for Common Variable Immunodeficiency. Liver Transplantation, 2021, 27, 456-458.	1.3	3
10	Clinical characteristics and outcomes of COVIDâ€19 in people living with HIV in Belgium: A multicenter, retrospective cohort. Journal of Medical Virology, 2021, 93, 2971-2978.	2.5	6
11	Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma. Scientific Reports, 2021, 11, 5817.	1.6	3
12	Can predicting COVID-19 mortality in a European cohort using only demographic and comorbidity data surpass age-based prediction: An externally validated study. PLoS ONE, 2021, 16, e0249920.	1.1	16
13	Lung and liver sarcoidosisâ€ike reaction induced by tocilizumab. British Journal of Clinical Pharmacology, 2021, 87, 4848-4852.	1.1	9
14	Decrease in late presentation for HIV care in Kinshasa, DRC, 2006–2020. AIDS Research and Therapy, 2021, 18, 41.	0.7	4
15	Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study. International Journal of Infectious Diseases, 2021, 109, 209-216.	1.5	36
16	Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infectious Diseases, 2021, 21, 910.	1.3	15
17	CD32+CD4+ memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice. IScience, 2021, 24, 101881.	1.9	10
18	Progressive phasing out of baseline CD4+ cell count testing for people living with HIV in Kinshasa, Democratic Republic of the Congo. Aids, 2021, 35, 841-843.	1.0	5

#	Article	IF	CITATIONS
19	Transmission of SARS-CoV-2 After COVID-19 Screening and Mitigation Measures for Primary School Children Attending School in Lià ge, Belgium. JAMA Network Open, 2021, 4, e2128757.	2.8	45
20	In-Depth Longitudinal Comparison of Clinical Specimens to Detect SARS-CoV-2. Pathogens, 2021, 10, 1362.	1.2	9
21	Longitudinal analysis of sociodemographic, clinical and therapeutic factors of HIV-infected individuals in Kinshasa at antiretroviral therapy initiation during 2006-2017. PLoS ONE, 2021, 16, e0259073.	1.1	2
22	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
23	Impact of the COVID-19 pandemic situation on HIV care in Liège, Belgium. HIV Research and Clinical Practice, 2021, 22, 63-70.	1.1	3
24	Impact of coronavirus pandemic and containment measures on HIV diagnosis. Epidemiology and Infection, 2020, 148, e185.	1.0	25
25	Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients. Aids, 2020, 34, 1151-1159.	1.0	10
26	Evolution of Drug Interactions With Antiretroviral Medication in People With HIV. Open Forum Infectious Diseases, 2020, 7, ofaa416.	0.4	15
27	A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol. BMC Pulmonary Medicine, 2020, 20, 317.	0.8	12
28	Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	11
29	Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients. Acta Clinica Belgica, 2019, 74, 143-150.	0.5	0
30	Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients. Acta Clinica Belgica, 2018, 73, 1-7.	0.5	1
31	Wild-type HIV infection despite PrEP: a lot to learn from a case report. Lancet HIV,the, 2018, 5, e10.	2.1	0
32	Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study. Acta Clinica Belgica, 2018, 73, 50-53.	0.5	6
33	Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. Frontiers in Immunology, 2018, 9, 2012.	2.2	79
34	Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses Against Streptococcus pneumoniae. Frontiers in Immunology, 2018, 9, 2175.	2.2	13
35	Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine, 2018, 379, 1178-1180.	13.9	15
36	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	13.9	327

#	Article	IF	CITATIONS
37	Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. Journal of Allergy and Clinical Immunology, 2018, 142, 1932-1946.	1.5	344
38	Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017. Scientific Reports, 2018, 8, 8594.	1.6	32
39	lgG4-Related Disease Causing Rapid Evolution of a Severe Aortic Valvular Stenosis. Annals of Thoracic Surgery, 2017, 103, e239-e240.	0.7	6
40	IgG4-related membranous glomerulonephritis and generalized lymphadenopathy without pancreatitis: a case report. BMC Nephrology, 2017, 18, 139.	0.8	8
41	The <scp>BEACH</scp> protein <scp>LRBA</scp> is required for hair bundle maintenance in cochlear hair cells and for hearing. EMBO Reports, 2017, 18, 2015-2029.	2.0	12
42	The effect of treatment simplification on HIV reservoirs. Lancet HIV, the, 2017, 4, e328-e329.	2.1	9
43	Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner. PLoS ONE, 2017, 12, e0185786.	1.1	14
44	Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium. PLoS ONE, 2017, 12, e0185761.	1.1	16
45	Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics: Targets and Therapy, 2016, 10, 75.	3.0	66
46	18F-FDG PET/CT in the Management of Aortitis. Clinical Nuclear Medicine, 2016, 41, 28-33.	0.7	24
47	sCD14 is not a bona-fide biomarker of microbial translocation in HIV-1-infected Africans living in Belgium. Aids, 2016, 30, 921-924.	1.0	11
48	Increased extrafollicular expression of the B-cell stimulatory molecule CD70 in HIV-1-infected individuals. Aids, 2015, 29, 1757-1766.	1.0	7
49	Deficiency of Interleukin-1 Receptor-associated Kinase 4 Presenting as Fatal Pseudomonas aeruginosa Bacteremia in Two Siblings. Pediatric Infectious Disease Journal, 2015, 34, 299-300.	1.1	9
50	An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathogens, 2015, 11, e1005063.	2.1	229
51	Dual-Specificity Phosphatase 3 Deficiency or Inhibition Limits Platelet Activation and Arterial Thrombosis. Circulation, 2015, 131, 656-668.	1.6	42
52	DUSP3 Genetic Deletion Confers M2-like Macrophage–Dependent Tolerance to Septic Shock. Journal of Immunology, 2015, 194, 4951-4962.	0.4	28
53	CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba. EBioMedicine, 2015, 2, 244-254.	2.7	56
54	Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. Journal of Antimicrobial Chemotherapy, 2015, 70, 207-216.	1.3	55

#	Article	IF	CITATIONS
55	Factors associated with the continuum of care of HIV-infected patients in Belgium. Journal of the International AIDS Society, 2014, 17, 19534.	1.2	17
56	<i>Mortierella wolfii</i> àê"Associated Invasive Disease. Emerging Infectious Diseases, 2014, 20, 1591-1592.	2.0	14
57	The <scp>RIAD</scp> peptidomimetic inhibits <scp>HIV</scp> â€1 replication in humanized <scp>NSG</scp> mice. European Journal of Clinical Investigation, 2014, 44, 146-152.	1.7	9
58	Minocycline attenuates <scp>HIV</scp> â€l infection and suppresses chronic immune activation in humanized <scp>NOD</scp> /LtsZâ€scid <scp>IL</scp> â€2R <i>l³</i> <sup>null</sup> mice. Immunology, 2014, 142, 562-572.	2.0	19
59	DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase. Molecular Cancer, 2014, 13, 108.	7.9	40
60	Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia, 2013, 56, 2487-2497.	2.9	202
61	Use of Dried Blood Spot to Improve the Diagnosis and Management of HIV in Resource-Limited Settings. World Journal of AIDS, 2013, 03, 251-256.	0.1	6
62	An Improved Protocol for Efficient Engraftment in NOD/LTSZ-SCIDIL-2RγNULL Mice Allows HIV Replication and Development of Anti-HIV Immune Responses. PLoS ONE, 2012, 7, e38491.	1.1	31
63	Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity. American Journal of Human Genetics, 2012, 90, 986-1001.	2.6	452
64	A pauci-symptomatic case of documented Hantavirus (Puumala) infection in a patient under anti-TNF treatment. Journal of Clinical Virology, 2011, 50, 247-248.	1.6	2
65	Mucosal junctions: open doors to HPV and HIV infections?. Trends in Microbiology, 2011, 19, 114-120.	3.5	46
66	Humanized mice as a useful model to study HIV-1 induced immune activation, its mechanisms and potential therapeutic approaches. Retrovirology, $2011, 8, .$	0.9	0
67	Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. Journal of Antimicrobial Chemotherapy, 2011, 66, 265-272.	1.3	22
68	Syphilis Treatment in the Human Immunodeficiency Virus-Infected Patient: Follow the Guidelines. Clinical Infectious Diseases, 2011, 53, 845-845.	2.9	2
69	Mice with Disrupted Type I Protein Kinase A Anchoring in T Cells Resist Retrovirus-Induced Immunodeficiency. Journal of Immunology, 2011, 186, 5119-5130.	0.4	17
70	Fibromyalgia and related conditions: Electromyogram profile during isometric muscle contraction. Joint Bone Spine, 2010, 77, 264-267.	0.8	8
71	HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Research and Therapy, 2010, 7, 4.	0.7	36
72	Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology, 2010, 49, 1815-1827.	0.9	176

#	Article	IF	CITATIONS
73	Thymic self-antigens for the design of a negative/tolerogenic self-vaccination against type 1 diabetes. Current Opinion in Pharmacology, 2010, 10, 461-472.	1.7	23
74	Gentamicin in Infective Endocarditis: How to Use It?. Clinical Infectious Diseases, 2009, 49, 320-321.	2.9	3
75	Autoimmune Angioneurotic Edema in a Patient with <i> Helicobacter pylori</i> Infection. Helicobacter, 2009, 14, 9-11.	1.6	5
76	Selective defect of anti-pneumococcal IgG in a patient with persistent polyclonal B cell lymphocytosis. European Journal of Internal Medicine, 2009, 20, e62-e65.	1.0	3
77	Multidentate Small-Molecule Inhibitors of <i>Vaccinia</i> H1-Related (VHR) Phosphatase Decrease Proliferation of Cervix Cancer Cells. Journal of Medicinal Chemistry, 2009, 52, 6716-6723.	2.9	53
78	Impact of Growth Hormone (GH) Deficiency and GH Replacement upon Thymus Function in Adult Patients. PLoS ONE, 2009, 4, e5668.	1.1	48
79	Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection. PLoS ONE, 2009, 4, e6093.	1.1	222
80	Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer, 2008, 8, 147.	1.1	53
81	Decline of antibiotic use in primary care. Lancet Infectious Diseases, The, 2008, 8, 272.	4.6	1
82	Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006. AIDS Research and Human Retroviruses, 2008, 24, 355-362.	0.5	33
83	Report of a Case of Streptococcus agalactiae Mycotic Aneurysm and Review of the Literature. International Journal of Surgical Pathology, 2008, 16, 314-319.	0.4	11
84	In Vivo Administration of a PKA Type I Inhibitor (Rp-8-Br-cAMPS) Restores T-Cell Responses in Retrovirus-Infected Mice. The Open Immunology Journal, 2008, 1, 20-24.	1.5	4
85	Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epsteinâ€Barr Virus Vaccine in Healthy Young Adults. Journal of Infectious Diseases, 2007, 196, 1749-1753.	1.9	347
86	A Patient with HIV Infection, Cough, Asthenia, and Fever. Clinical Infectious Diseases, 2007, 45, 599-600.	2.9	0
87	Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults. Vaccine, 2007, 25, 4697-4705.	1.7	140
88	Downregulation of CD94/NKG2A inhibitory receptors on CD8+T cells in HIV infection is more pronounced in subjects with detected viral load than in their aviraemic counterparts. Retrovirology, 2007, 4, 72.	0.9	19
89	HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-α+TSA. Biochemical Pharmacology, 2007, 73, 1738-1748.	2.0	22
90	Loss of the VHR dual-specific phosphatase causescell-cycle arrest and senescence. Nature Cell Biology, 2006, 8, 524-531.	4.6	114

#	Article	IF	CITATIONS
91	Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway. Biochemical Pharmacology, 2005, 70, 714-724.	2.0	38
92	Removal of C-Terminal Src Kinase from the Immune Synapse by a New Binding Protein. Molecular and Cellular Biology, 2005, 25, 2227-2241.	1.1	31
93	Current Levels of Drug Resistance Among Therapy-Naive HIV-Infected Patients Have Significant Impact on Treatment Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1664-1666.	0.9	25
94	Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice. Biochemical Journal, 2004, 384, 469-476.	1.7	27
95	Performance of the VERSANTÃ, $\hat{A}$ ®HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes. FEMS Immunology and Medical Microbiology, 2003, 39, 119-124.	2.7	10
96	HIV-Associated Hematologic Disorders Are Correlated With Plasma Viral Load and Improve Under Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 221-225.	0.9	64
97	Increased cAMP levels and protein kinase (PKA) type I activation in CD4+ T cells and B cells contribute to the retrovirusâ€induced immunodeficiency of mice (MAIDS). A useful in vivo model for drug testing in PKA type Iâ€induced immunodeficiency. FASEB Journal, 2001, 15, 1466-1468.	0.2	20
98	HIV-Associated Hematologic Disorders Are Correlated With Plasma Viral Load and Improve Under Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 221-225.	0.9	2
99	Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells. Cancer Gene Therapy, 2000, 7, 676-682.	2.2	14
100	Decreased Protein Levels of the c-Cbl Protooncogene in Murine AIDS. Cellular Immunology, 1998, 188, 151-157.	1.4	5
101	Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix., 1998, 184, 283-290.		85
102	CD28-B7 Costimulatory Blockade by CTLA4lg Delays the Development of Retrovirus-Induced Murine AIDS. Journal of Virology, 1998, 72, 5285-5290.	1.5	17
103	Improved four-color flow cytometry method using fluo-3 and triple immunofluorescence for analysis of intracellular calcium ion ( $[Ca2+]i$ ) fluxes among mouse lymph node B- and T-lymphocyte subsets., 1996, 23, 205-217.		36
104	Subset-specific analysis of calcium fluzes in murine AIDS. International Immunology, 1996, 8, 1715-1727.	1.8	11